<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741581</url>
  </required_header>
  <id_info>
    <org_study_id>20.18.CLI</org_study_id>
    <nct_id>NCT04741581</nct_id>
  </id_info>
  <brief_title>ThickenUp® Gel Express for Patients With Dysphagia</brief_title>
  <acronym>HYDRA-01</acronym>
  <official_title>Effect on Swallowing Function as Assessed by a Videofluoroscopy (VFS) One Day Study With Bolus of Various Viscosities, Followed, in a Subset of Patients, by an Acceptability 14 Days Study Combined With an Exploratory Hydration Assessment Study at a Prescribed Viscosity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of swallowing function and hydration following consumption of ThickenUp® Gel&#xD;
      Express in patients with dysphagia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ThickenUp® Gel Express for Patients With Dysphagia (&quot;Hydra-01 Study&quot;): Effect on Swallowing&#xD;
      Function as Assessed by a Videofluoroscopy (VFS) One Day Study With Bolus of Various&#xD;
      Viscosities (Study Part 1) and Followed, in a Subset of Patients, by a United Kingdom&#xD;
      Advisory Committee on Borderline Substances (UK ACBS) Acceptability 14 Days Study Combined&#xD;
      With an Exploratory Hydration Assessment Study at a Prescribed Viscosity (Study Part 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">April 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, open-label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Appendicitis Score (PAS)</measure>
    <time_frame>1 day</time_frame>
    <description>Part 1 -Bolus penetration into the laryngeal vestibule (PAS Score): the maximum PAS score across the different boluses assessed during videofluoroscopic (VFS) recording.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The United Kingdom Advisory Committee on Borderline Substances (UK ACBS)</measure>
    <time_frame>14 days</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dysphagia, Esophageal</condition>
  <arm_group>
    <arm_group_label>Thicken up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Assess the effect of ThickenUp® Gel Express at increasing viscosities (slightly thick, nectar, honey, and pudding) on swallowing function compared to water using VFS (N=100), in patients affected by Oropharyngeal dysphagia (OD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ThickenUp® Gel Express</intervention_name>
    <description>Thickening gel</description>
    <arm_group_label>Thicken up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 years;&#xD;
&#xD;
          2. Diagnosed with oropharyngeal dysphagia and with a documented impaired safety of&#xD;
             swallow by V-VST;&#xD;
&#xD;
          3. History and/or current of swallowing difficulties;&#xD;
&#xD;
          4. Willing to adhere to the restrictions specified in the protocol;&#xD;
&#xD;
          5. Must be competent to understand the nature of the study and capable of giving written&#xD;
             informed consent. In case patients are not capable of providing written informed&#xD;
             consent (i.e. dementia) a family/legal representative could provide the consent for&#xD;
             the study;&#xD;
&#xD;
          6. Willing to report for the scheduled study visits and communicate to study personnel&#xD;
             about adverse events and concomitant medication use.&#xD;
&#xD;
        Additional inclusion criteria for study part 2 only:&#xD;
&#xD;
          1. Patient willing to participate in study part 2;&#xD;
&#xD;
          2. Patient caregiver able to record daily GI symptoms, compliance and fluid intake;&#xD;
&#xD;
          3. Patient able to respond to acceptability questionnaire (organoleptic properties,&#xD;
             texture, appearance).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients suffering from idiosyncratic phenomena or who are allergic to iodinated&#xD;
             contrast media;&#xD;
&#xD;
          2. Major respiratory disease requiring oxygen or undergoing any type of surgery in the&#xD;
             three months prior to the study;&#xD;
&#xD;
          3. Current diarrhea, vomiting or abdominal pain;&#xD;
&#xD;
          4. Alcohol or drug dependence (based on the anamnesis only);&#xD;
&#xD;
          5. COVID-19 positive patients (with or without symptoms);&#xD;
&#xD;
          6. Patients who, in the judgment of the investigator, are likely to be non-compliant or&#xD;
             uncooperative during the study, or unable to cooperate because of a language problem,&#xD;
             poor mental development;&#xD;
&#xD;
          7. Having participated in a clinical study in the last 4 weeks and received compensation&#xD;
             beyond a certain approved and predefined limit;&#xD;
&#xD;
          8. Having a clinical condition that is contraindicated with the study product.&#xD;
&#xD;
          9. Positive urine pregnancy test at screening for women of childbearing potential&#xD;
&#xD;
         10. Allergy towards milk, mustard, egg, or celery.&#xD;
&#xD;
        Additional exclusion criteria for study part 2:&#xD;
&#xD;
          1. Undergone a major gastrointestinal surgery less than 3 months prior to enrollment in&#xD;
             this study;&#xD;
&#xD;
          2. Obstruction of the gastrointestinal tract.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Clavé, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Mataró</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elham Pazirandeh Micol</last_name>
    <phone>+ 41 76 674 1360</phone>
    <email>elham.pazirandehmicol@nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Clavé</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deglutition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

